What the FDA labels say about taking them together
Aprepitant and pimozide
Aprepitant's FDA label of July 5, 2024 names pimozide in its contraindications section; the pimozide label PlainMeds reads does not name aprepitant. The aprepitant label: “Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated.”
Check it at the source: the aprepitant FDA label on DailyMed (effective July 5, 2024, Merck Sharp & Dohme LLC); the pimozide FDA label on DailyMed (effective August 12, 2026, Par Health USA, LLC).
What does the aprepitant label say about pimozide?
Aprepitant label, contraindicationsInhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of this drug which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Warnings and Precautions (5.1) ].
Aprepitant label, drug interactionsEffects of Aprepitant on the Pharmacokinetics of Other Drugs CYP3A4 Substrates Pimozide Clinical Impact Increased pimozide exposure. Intervention EMEND is contraindicated [see Contraindications (4) ].
Aprepitant label, warnings and precautionsUse of pimozide with EMEND is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide [see Contraindications (4) ].
Cinvanti label (Heron Therapeutics, Inc., April 1, 2026), contraindicationsInhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of pimozide, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Warnings and Precautions (5.1) ].
Source: FDA drug label (Cinvanti, NDA209296), Heron Therapeutics, Inc., effective April 1, 2026 (SPL set 4c218d3a-a508-4abc-9ed8-a6e8e191d1b4), via openFDA
Source: FDA drug label (EMEND), NDA021549 (Msd), as published by Merck Sharp & Dohme LLC, effective July 5, 2024 (SPL set 696f9e80-9cae-403b-de9e-078343ce4713), via openFDA; the full label on DailyMed
What does the pimozide label say about aprepitant?
Pimozide's label (effective August 12, 2026) does not name aprepitant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pimozide), Par Health USA, LLC, effective August 12, 2026 (SPL set 70b079e2-a1f7-4a93-8685-d60a4d7c1280), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aprepitant | Pimozide | |
|---|---|---|
| Labeled for | Nausea and vomiting | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $46.42 per capsule 40 mg capsule | $1.23 per tablet 1 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once